The anticancer phytochemical rocaglamide inhibits Rho GTPase activity and cancer cell migration

• DOI: 10.18632/oncotarget.10188
• Publication Date: 2016-06-20T20:44:37Z
• Authors: Michael S. Becker; Paul M. Müller; Jörg Bajorat; Anne Schroeder; Marco Giaisi; Ehsan Amin; Mohammad R. Ahmadian; Oliver Rocks; Rebecca Köhler; Peter H. Krammer; Min Li-Weber
• Keywords: Phytochemical

// Michael S. Becker 1 , Paul M. Müller 2 Jörg Bajorat Anne Schroeder Marco Giaisi Ehsan Amin 3 Mohammad R. Ahmadian Oliver Rocks Rebecca Köhler Peter H. Krammer Min Li-Weber Tumorimmunology Program (D030), German Cancer Research Center (DKFZ), INF-280, Heidelberg, Germany Max Delbrück for Molecular Medicine Berlin-Buch, Berlin, Institute of Biochemistry and Biology II, Medical Faculty The Heinrich-Heine University, Düsseldorf, Correspondence to: Li-Weber, email: [e-mail] Keywords: flavaglines, rocaglamide, cell migration, Rho GTPase Received: October 23, 2015 Accepted: June 04, 2016 Published: 20, ABSTRACT Chemotherapy is one the pillars anti-cancer therapy. Although chemotherapeutics cause regression primary tumor, many are often shown to induce or accelerate metastasis formation. Moreover, metastatic tumors largely resistant against chemotherapy. As more than 90% cancer patients die due metastases not tumor formation, novel drugs needed overcome these shortcomings. In this study, we identified anticancer phytochemical Rocaglamide (Roc-A) be an inhibitor a crucial event in We show that Roc-A inhibits cellular migration invasion independently its anti-proliferative cytotoxic effects different types human cells. Mechanistically, treatment induces F-actin-based morphological changes membrane protrusions. Further investigation molecular mechanisms revealed activities small GTPases RhoA, Rac1 Cdc42, master regulators migration. Taken together, our results provide evidence may lead candidate new class inhibit